Table 2 Baseline characteristics of the whole sample considered for the meta-analysis
| Â | Â | Â | AR | Â | NAR | Â | Â | Â | Â |
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | N of studies with data | N (%) | N total | N (%) | N total | RR (95%CI) | P | I2 |
Sex | Female | 8 | 211 (21.4%) | 984 | 181 (20.6%) | 877 | 1.05 (0.88, 1.26) | 0.40 | 4% |
Liver function | Child A | 7 | 755 (99.3%) | 760 | 752 (98.9%) | 760 | 1.00 (0.99, 1.02) | 0.72 | 0% |
Viral hepatitis status | HBV | 6 | 410 (46.5%) | 881 | 335 (43.3%) | 774 | 1.01 (0.96, 1.06) | 0.79 | 0% |
| Â | HCV | 6 | 283 (32.1%) | 881 | 261 (33.7%) | 774 | 1.04 (0.91, 1.19) | 0.99 | 0% |
Number of nodules | Single | 8 | 935 (95.0%) | 984 | 848 (96.7%) | 877 | 0.99 (0.98, 1.01) | 0.51 | 0% |
Microvascular invasion | Presence | 8 | 236 (24.0%) | 984 | 230 (26.2%) | 877 | 0.99 (0.85, 1.14) | 0.98 | 0% |
Morbidity | Overall complications | 3 | 88 (20.0%) | 441 | 80 (18.1%) | 441 | 1.10 (0.84, 1.44) | 0.41 | 0% |
Major complications | 2 | 5 (5.7%) | 87 | 4 (4.6%) | 87 | 1.25 (0.35, 4.51) | 0.34 | 0% |